WASHINGTON (Reuters) - The company that makes the highly popular narcotic painkiller Darvon has pulled the drug from the market because it can cause fatal heart rhythms, the U.S. Food and Drug Administration said on Friday.
JOHANNESBURG (Reuters) - South Africa could cut the number of new HIV infections to below 200,000 a year by 2020, more than half the current level, with the right policies, but reaching the goal will be costly, a report on Friday said.
NEW YORK (Reuters) - U.S. regulators warned makers of caffeinated alcoholic drinks that their products are unsafe and violate federal laws, following a public outcry and several state bans.
WASHINGTON (Reuters) - Senate Republicans decried the cost of Medicare and Medicaid and accused the Obama administration of blocking their oversight of the federally supported insurance programs for the elderly and the poor, at a hearing on Wednesday.
WASHINGTON (Reuters) - A third of Americans say they have gone without medical care or skipped filling a prescription because of cost, compared to 5 percent in the Netherlands, according to study released on Thursday.
CHICAGO (Reuters) - U.S. military veterans who have post-traumatic stress disorder — a condition marked by severe anxiety, sleep disruptions, hyperarousal and impaired concentration — have double the risk of dying and a greater risk of developing cardiovascular disease, researchers said on Wednesday.
LOS ANGELES (Reuters) - If the threat of earthquakes, wildfires and mudslides isn’t enough to worry Los Angeles residents, public health officials are now warning of an unusually high number of rabid bats.
WASHINGTON (Reuters) - Mistakes and unavoidable problems kill an estimated 15,000 elderly U.S. patients every month in hospitals, U.S. government investigators reported on Tuesday.
LONDON (Reuters) - The severity of Parkinson’s disease symptoms could be monitored remotely by analyzing speech patterns, saving health authorities time and money and easing the burden on patients, scientists said Wednesday.
ADELPHI, Maryland (Reuters) - The first new lupus treatment in half a century moved closer to U.S. approval on Tuesday as an advisory panel endorsed a potential blockbuster medicine from Human Genome Sciences Inc.